
Bal Pharma Ltd. (BALPHARMA): Bal Pharma Share Price rises 17.92% as stock trades at Rs 112.05
Updated: 9 Sept 2026 • 10:24 am
Posted by:

Bal Pharma Share Price rose 17.92% to Rs 112.05, with market capitalisation at Rs 147.81 Cr. The move lifted Bal Pharma Ltd. into focus in today’s market update, even though the latest Univest data does not establish a company-specific catalyst.
Bal Pharma Share Price is trading higher today, and the move has drawn attention in Bal Pharma Stock News and Bal Pharma Share Price Today searches. The stock last traded at Rs 112.05, up Rs 17.03 or 17.92% from the previous close of Rs 95.02, while market capitalisation stood at Rs 147.81 Cr. The latest Univest figures confirm a strong share price rise, but they do not establish a company-specific trigger for the move.
Bal Pharma Share Price Today: Price Action Analysis
That makes the stock relevant for readers tracking Stocks in News and Top Gainers Today in the Indian stock market. Bal Pharma Share Price today therefore becomes a case study in price action, valuation context and sector positioning rather than a catalyst-led story. Investors can monitor whether the move is sustained around the day’s high of Rs 112.05 and how the stock behaves relative to its healthcare peers.
| Metric | Value |
|---|---|
| Current Price | Rs 112.05 |
| Previous Close | Rs 95.02 |
| Today's Move | Rs 17.03 (+17.92%) |
| Open | Rs 94.94 |
| High | Rs 112.05 |
| Low | Rs 94.94 |
| Turnover | Rs 0.47 crore |
| Market Capitalisation | Rs 147.81 crore |
| Market Cap Category | Micro Cap |
Bal Pharma Ltd. (BALPHARMA) rose to Rs 112.05 from the previous close of Rs 95.02, a move of Rs 17.03 or 17.92%. The stock opened at Rs 94.94, reached a high of Rs 112.05, recorded a low of Rs 94.94.
Bal Pharma Share Price opened at Rs 94.94 and moved steadily to Rs 112.05, which was also the day’s high, after touching a low of Rs 94.94. The gain of Rs 17.03 from the previous close shows a clear intraday share price rise and places Bal Pharma among the sharper movers in today’s share market today action. Turnover was Rs 0.47 Cr.
The latest Univest data confirms that the stock’s move was sharp enough to stand out in Bal Pharma Stock Gaining Today searches, but the data alone does not identify a stock-specific reason. For readers scanning Bal Pharma Share Price Live or Bal Pharma Share Price Update, the key point is that the move happened within a narrow range from the open to the high, with price action remaining straightforward and directional.
Bal Pharma Ltd. (BALPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 147.81 crore |
| P/E Ratio | 20.99x |
| P/B Ratio | 1.81x |
| ROE | 7.92% |
| ROCE | 9.78% |
| EPS | Rs 4.53 |
| Book Value Per Share | Rs 52.36 |
| Dividend Yield | 1.26% |
Bal Pharma Ltd. (BALPHARMA) fundamental metrics show P/E 20.99x, P/B 1.81x, ROE 7.92%, ROCE 9.78%. These figures provide context only and are not a buy or sell signal.
Bal Pharma Ltd. has a market capitalisation of Rs 147.81 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 20.99x, P/B at 1.81x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 7.92% and ROCE of 9.78%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 4.53, book value per share of Rs 52.36, dividend yield of 1.26%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.19x, median ROE of 11.82%, median ROCE of 13.71%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 20.99x |
| Benchmark Median P/E | 32.19x |
| Benchmark Average P/E | 49.13x |
| Benchmark P/E Range | 3.39x to 668.68x |
| Company P/B Ratio | 1.81x |
| Benchmark Median P/B | 3.05x |
| Company ROE | 7.92% |
| Benchmark Median ROE | 11.82% |
| Company ROCE | 9.78% |
| Benchmark Median ROCE | 13.71% |
| Company Market Capitalisation | Rs 147.81 crore |
| Benchmark Median Market Cap | Rs 715.6 crore |
Bal Pharma Ltd. (BALPHARMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Bal Pharma Ltd. (BALPHARMA) has a P/E ratio of 20.99x, which is below the benchmark median of 32.19x, a difference of -34.79%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Bal Pharma Ltd. (BALPHARMA) has a ROE of 7.92%, which is below the benchmark median of 11.82%, a difference of -32.99%. Bal Pharma Ltd. (BALPHARMA) has a ROCE of 9.78%, which is below the benchmark median of 13.71%, a difference of -28.67%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,55,825.66 | 37.31 | 5.22 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,47,018.51 | 86.86 | 14.38 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,86,874.73 | 86.55 | 21.03 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,211.69 | 25.42 | 4.25 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,12,773 | 33.17 | 3.18 | 11.83 | 16 |
Bal Pharma Ltd. (BALPHARMA) has a P/E ratio of 20.99x compared with the displayed peer median of 37.31x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 7.92% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 9.78% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Bal Pharma Ltd. (BALPHARMA) has a market capitalisation of Rs 147.81 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Bal Pharma
- Bal Pharma Share Price rose 17.92% to Rs 112.05, making it a notable mover in today’s market.
- The stock traded from Rs 94.94 to Rs 112.05, showing a clean intraday price action pattern.
- Market capitalisation of Rs 147.81 Cr keeps Bal Pharma in the small-cap bracket.
- P/E of 20.99 and P/B of 1.81 place Bal Pharma below the industry valuation centre.
- ROE of 7.92% and ROCE of 9.78% give investors a basic read on return quality.
About Bal Pharma
Bal Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. The company is tracked on both NSE and BSE, and Bal Pharma Share Price today reflects how the market is currently assessing a smaller pharmaceutical name. With market capitalisation at Rs 147.81 Cr, the company sits well below the larger listed healthcare leaders.
From the available financial profile, the business is valued at a P/E of 20.99 and a P/B of 1.81, while EPS is Rs 4.53 and book value is Rs 52.36 per share. The dividend yield of 1.26% adds another layer to the profile, though the latest move in Bal Pharma Stock News is clearly driven by price action rather than a publicly identified event. For readers following Bal Pharma Share Price Rise and Bal Pharma Share Price News, the company remains a small healthcare participant with visible market attention today.
Frequently Asked Questions
Why is Bal Pharma Share Price rising today?
Ans. Bal Pharma Share Price rose 17.92% to Rs 112.05, but the latest Univest figures do not establish a company-specific catalyst. The move is visible in price action, not in a disclosed event-based trigger.
What is Bal Pharma Share Price today?
Ans. Bal Pharma Share Price today is Rs 112.05. It was up Rs 17.03 from the previous close of Rs 95.02, which makes it a clear intraday gainer in the healthcare space.
What is Bal Pharma market capitalisation?
Ans. Bal Pharma’s market capitalisation is Rs 147.81 Cr. That size places it in the small-cap category and helps explain why a single-day share price rise can change attention quickly.
What does Bal Pharma P/E ratio indicate?
Ans. Bal Pharma’s P/E ratio is 20.99. It is below the same-industry median of 32.19, which gives the stock a lower valuation read than many other pharmaceuticals names in the benchmark set.
How does Bal Pharma compare with pharma peers?
Ans. Bal Pharma Share Price is being compared with larger peers such as Sun Pharma, Cipla, Zydus Lifesciences and Divi’s Laboratories. Its valuation and market cap are much smaller than those companies.
What are Bal Pharma EPS and book value?
Ans. Bal Pharma EPS is Rs 4.53 and book value is Rs 52.36 per share. EPS shows earnings attributable to each share, while book value reflects accounting net worth per share.
Does Bal Pharma offer a dividend yield?
Ans. Yes, Bal Pharma’s dividend yield is 1.26%. That figure reflects historical or current payout context and should be read alongside valuation, return ratios and overall stock performance.
Where can I track Bal Pharma Share Price Live?
Ans. You can track Bal Pharma Share Price Live on Univest, along with market cap, sector comparison, valuation ratios and market updates. It is useful for monitoring Bal Pharma Share Price Today and related stock news.
Track Bal Pharma Share Price on Univest
Use Bal Pharma Ltd. (BALPHARMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors can track Bal Pharma Share Price on Univest for live price updates, key fundamental ratios, sector comparison, and company overview. The platform also helps users follow Bal Pharma Share Price Today, Bal Pharma Stock News and Bal Pharma Latest News in one place.
Univest also lets readers monitor market cap, earnings metrics, valuation ratios and broader market context for Bal Pharma Share Price. If you are reviewing Bal Pharma Stock Analysis or Bal Pharma Share Price Update, Univest keeps the company view easy to compare with sector peers.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Recent Articles

Netweb Technologies India (NETWEB) Share Price Falls 2.47% to Rs 4,962
9 September 2026

HDFC Life Insurance Company (HDFCLIFE): HDFC Life Share Price Falls 2.62% to Rs 520: Price Action, Valuation and Sector View
9 September 2026

Nifty Auto Today: Index Falls 0.91% in Early Trade
9 September 2026

Sunlite Recycling Industries Ltd. (SUNLITE-SM): Sunlite Recycling Industries Share Price rises 8.24% as stock gains today
9 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Netweb Technologies India (NETWEB) Share Price Falls 2.47% to Rs 4,962
HDFC Life Insurance Company (HDFCLIFE): HDFC Life Share Price Falls 2.62% to Rs 520: Price Action, Valuation and Sector View
Nifty Auto Today: Index Falls 0.91% in Early Trade
Sunlite Recycling Industries Ltd. (SUNLITE-SM): Sunlite Recycling Industries Share Price rises 8.24% as stock gains today
Nifty IT Today: Index Slips 2.94% in Early Trade
Popular this week
HLE Glascoat Ltd. (HLEGLAS): HLE Glascoat Share Price Rises 8.44% as Stock Trades Higher Today

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





